Targeted radiation therapy for advanced cancers with SSTR2 and integrin markers
Part of Cancer clinical trials.
This trial tests a new radioactive drug (177Lu-TATE-RGD) that targets two specific markers on tumor cells. It is for people whose cancer has not responded to standard treatments and whose tumors show high levels of these markers on a PET scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a cancer that is confirmed by a biopsy and standard treatments have stopped working or are not suitable.
- A special PET scan (68Ga-TATE-RGD) must show your tumor has high levels of two specific markers (SSTR2 and integrin αVβ3).
- Your kidneys, liver, and blood cell counts need to be within certain healthy limits (doctor will check).
- You must not have significant heart valve disease caused by your tumor.
- You cannot have severe allergies to contrast dye or claustrophobia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy drug (Tislelizumab) as maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific protein (SSTR). If you have completed first-line treatment and your cancer shows SSTR on a PET scan, this study may be an option.
This trial tests a new radioactive drug (177Lu-AB-3PRGD2) that targets a protein called integrin αvβ3 found on many solid tumors. It is for people whose cancer has not responded to or has come back after several standard treatments.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
This trial tests a new targeted radioactive drug that seeks out a specific marker on lung cancer cells. It first uses a low-dose imaging scan to see if the cancer cells have this marker, then gives a higher-dose treatment to destroy those cells.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
Hear when a new SSTR2 and Integrin αVβ3 Positive Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.